Floatz logo

Arq 092

Endometrial Cancer

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

234 Active assets in the Endometrial Cancer cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Istanbul University
Phase 4BB
Inno-206
AstraZeneca
Phase 3BB
Olaparib
Qilu Pharmaceutical Co., Ltd.
Phase 4BB
Palbociclib
University Medical Center Groningen
Phase 4BB
FILGRASTIM
Mayo Clinic
Phase 3B

View all 50 →

Same molecule, other indications

Arq 092 is also rated in:

lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →
ovarian cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →